A PET/MRI system combines simultaneous positron emission tomography with high-field MRI, enabling molecular imaging of metabolic and physiologic processes alongside the anatomical and functional detail that MRI provides. The integration is technically demanding: the PET detector ring must operate within the bore of the superconducting magnet without the avalanche photodiodes being disrupted by the magnetic field, which requires silicon photomultiplier technology that is fundamentally different from the photomultiplier tubes used in conventional PET/CT systems. The result is a scanner that costs more than PET/CT, requires more complex siting, and serves a more selective clinical and research market.
Financing a PET/MRI system involves the same total-project thinking we apply to conventional 3T MRI installations, expanded to include the regulatory and safety considerations associated with the PET component: radiopharmaceutical handling, radiation shielding requirements beyond the RF shielding for the MRI component, and either an on-site cyclotron or a proximity arrangement with a commercial radiopharmacy. We structure the financing around the real project cost from the beginning.
PET/MRI System Costs and Configuration
Clinical PET/MRI systems are among the most expensive items in diagnostic imaging capital equipment. Major system configurations from primary vendors are priced at approximately $3 million to $6 million for the scanner itself, depending on the MRI field strength (commonly 3T), the PET detector configuration, and the software package. This price point reflects the silicon photomultiplier detector technology, the engineering required to isolate the PET electronics from the MRI field, and the proprietary integration software that handles simultaneous acquisition and reconstruction.
Beyond the scanner price, the total project cost for a PET/MRI installation includes all of the MRI siting costs at a 3T specification level, plus the additional radiation shielding required for the PET component. A room that meets 3T MRI shielding requirements does not automatically meet PET radiation shielding requirements. A certified radiation physicist must design the shielding specification for the entire suite, which involves calculating scatter, primary beam paths, and the expected activity levels of the radiopharmaceuticals in use. That additional shielding adds cost and may affect room geometry planning. The chiller and quench vent requirements follow the same specification as any 3T superconducting installation and should be costed into the project budget from the beginning.
Radiopharmaceutical supply is a separate capital and operational consideration. Programs with on-site cyclotrons finance the cyclotron as a distinct capital asset, which can add $2 million to $4 million to the total program investment. Programs relying on a commercial radiopharmacy supply must be within the delivery window for short-lived isotopes, particularly F-18 labeled FDG, which has an approximately 110-minute half-life and requires same-day delivery within a practical geographic radius.
Who Invests in PET/MRI
Academic medical centers with established PET programs and strong MRI infrastructure represent the primary buyer market for PET/MRI. The technology's research value, combining molecular and functional imaging in a single session, is well-suited to cancer biology, neuroscience, and cardiac research programs. Clinical PET/MRI is approved and reimbursed for selected oncology and neurology indications in the United States, and academic programs can deploy these systems for both clinical revenue and investigator-initiated research.
Oncology and cancer centers with high PET scan volumes and established MRI programs represent a second category. For specific indications such as primary bone tumors, soft tissue sarcomas, and pediatric cancer staging, the simultaneous acquisition capability of PET/MRI provides advantages over sequential PET/CT plus MRI, including reduced radiation dose from eliminating the CT component and better soft tissue characterization from the MRI component. The clinical justification for PET/MRI in these programs is supported by a growing body of literature.
Financing a PET/MRI Project
PET/MRI financing operates in the upper tier of medical equipment transactions. Projects in the $4 million to $8 million range, when the full installed cost including siting and radiation shielding is accounted for, require lenders with healthcare capital markets experience and an appetite for complex projects. We connect PET/MRI programs with lenders who have financed hybrid imaging systems before and understand how to structure the draw schedule across construction, shielding, and equipment delivery phases.
The transaction typically involves full financial disclosure: institutional financial statements, the project plan, the radiation safety officer's shielding report, the siting survey, and a revenue projection that models scan volume against the reimbursement schedule for the intended clinical indications. Research utilization may also be included in the model when the program has established grant funding or is operating under an institutional commitment to support the research component.
For programs that already operate a PET/CT system and are considering an upgrade or addition, a MRI Sale-Leaseback on the existing PET/CT equipment can generate capital that reduces the PET/MRI financing amount. Similarly, if the existing PET/CT carries a loan balance, a payoff-and-replace structure can be structured so both transactions close simultaneously. We model these combinations when they apply to the specific program's situation.
Begin Your PET/MRI Financing Conversation
PET/MRI is among the most complex imaging investments a program can undertake. The financing needs to reflect that complexity from the first conversation, not as an afterthought after the vendor quote is received. Contact us through our intake form and we will engage with lenders experienced in hybrid imaging capital projects.